<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084513</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365451</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>FCCC-03041</secondary_id>
    <secondary_id>NOVARTIS-FCCC-03041</secondary_id>
    <nct_id>NCT00084513</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer</brief_title>
  <official_title>Phase I of Trastuzumab and Imatinib Mesylate (Gleevec®, Formerly Known as STI-571) in Patients With Recurrent or Metastatic Her-2/Neu Expressing Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill&#xD;
      them or deliver tumor-killing substances to them without harming normal cells. Imatinib&#xD;
      mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their&#xD;
      growth and by stopping blood flow to the tumor. Giving trastuzumab together with imatinib&#xD;
      mesylate may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate&#xD;
      when given together with trastuzumab in treating patients with recurrent or metastatic&#xD;
      HER2/neu-expressing (producing) cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of imatinib mesylate when administered with&#xD;
           trastuzumab (Herceptin®) in patients with recurrent or metastatic&#xD;
           HER2/neu-overexpressing cancer.&#xD;
&#xD;
        -  Determine response in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate the number of circulating tumor cells with radiographic imaging in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of imatinib mesylate.&#xD;
&#xD;
      Patients receive trastuzumab (Herceptin®) IV over 90 minutes on day 1 and oral imatinib&#xD;
      mesylate once or twice daily on days 1-21. Courses repeat every 21 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 9-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of imatinib mesylate given concurrently with trastuzumab (Herceptin®) as measured by CTC v 3.0 at course 1</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response as measured by RECIST criteria every 9 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cells in blood as measured by Immunicom Cell PrepTM at baseline, every 3 weeks until week 9, and then with each disease re-evaluation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylation status of AKT, extracellular signal-regulated kinase (ERK), and KIT as measured by western blot and/or immunohistochemistry at baseline and week 9</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed cancer that overexpresses HER2/neu, measured&#xD;
             3+ by immunohistochemistry or positive by fluorescence in situ hybridization&#xD;
&#xD;
               -  Recurrent or metastatic disease&#xD;
&#xD;
          -  Meets 1 of the following criteria for measurable or evaluable disease:&#xD;
&#xD;
               -  Unidimensionally measurable disease at least 20 mm by conventional techniques OR&#xD;
                  at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Evaluable disease, defined as a lesion on physical examination or imaging study&#xD;
                  that can be assessed as to changes in size but cannot be clearly measured in 1&#xD;
                  dimension (e.g., pleural effusions, ascites, or bone disease)&#xD;
&#xD;
          -  No carcinomatous meningitis or untreated/uncontrolled metastatic brain parenchymal&#xD;
             disease&#xD;
&#xD;
               -  Prior controlled brain parenchymal disease allowed provided at least 8 weeks&#xD;
                  since prior therapy AND no symptomatic progression off corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and AST ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.0 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.3 mg/dL&#xD;
&#xD;
          -  No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ lower limit of normal by MUGA&#xD;
&#xD;
          -  No uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No ischemic heart disease requiring medication&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No uncontrolled or significant pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No active unresolved infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior trastuzumab (Herceptin®) allowed&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) to support blood counts&#xD;
&#xD;
          -  No other concurrent anticancer biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior chemotherapy for metastatic disease allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 7 days since prior antibiotics&#xD;
&#xD;
          -  No concurrent parenteral antibiotics&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation with warfarin&#xD;
&#xD;
               -  Concurrent mini-dose warfarin (1 mg/day) for prophylaxis of central venous&#xD;
                  catheter thrombosis allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret von Mehren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2010</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

